NLR作为转移性肾癌行减量肾切除术患者预后的生物标志物。

IF 1.9 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Biomarkers in medicine Pub Date : 2025-03-01 Epub Date: 2025-02-26 DOI:10.1080/17520363.2025.2471746

Huanrui Liu, Senlin Li, Fan Zhang, Weiyang He, Xin Gou, Xu Zhang, Yongpeng Xie

{"title":"NLR作为转移性肾癌行减量肾切除术患者预后的生物标志物。","authors":"Huanrui Liu, Senlin Li, Fan Zhang, Weiyang He, Xin Gou, Xu Zhang, Yongpeng Xie","doi":"10.1080/17520363.2025.2471746","DOIUrl":null,"url":null,"abstract":"Purpose: This study aimed to determine the prognostic value of preoperative Neutrophil-to-lymphocyte ratio (NLR) in patients with metastatic renal cell carcinoma (mRCC) undergoing cytoreductive nephrectomy (CN).Methods: We retrospectively investigated the clinicopathological data of patients with mRCC from two Chinese hospitals (2008-2018). Patients were stratified and analyzed for survival prognosis using X-tile software, Kaplan-Meier curves, log-rank test, and univariate/multivariate Cox regression analyses.Results: The patients were divided into low NLR group (≤2.7) and high NLR group (>2.7) based on the optimal cutoff value of 2.7 obtained using the X-tile software, containing 137 and 93 patients, respectively. Kaplan - Meier analysis indicated that high NLR group had significantly inferior median progression-free survival (PFS) and overall survival (OS) than low NLR group (median PFS of 8.3 months vs. 17.9 months, p = 0.003 and median OS of 21.6 months vs. 45.1 months, p = 0.009). Multivariate Cox regression analysis showed that NLR was an independent prognostic factor for PFS (hazard ratio [HR], 1.4; 95% CI, 1.1-1.9; p = 0.022) and OS (HR, 1.5; 95% CI, 1.1-2.1; p = 0.015).Conclusions: Elevated preoperative NLR demonstrates significant association with poor survival in post-CN mRCC patients and may facilitate clinical decision-making.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"215-222"},"PeriodicalIF":1.9000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11916357/pdf/","citationCount":"0","resultStr":"{\"title\":\"NLR as prognostic biomarker for metastatic renal cell carcinoma patients treated with cytoreductive nephrectomy.\",\"authors\":\"Huanrui Liu, Senlin Li, Fan Zhang, Weiyang He, Xin Gou, Xu Zhang, Yongpeng Xie\",\"doi\":\"10.1080/17520363.2025.2471746\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Purpose: This study aimed to determine the prognostic value of preoperative Neutrophil-to-lymphocyte ratio (NLR) in patients with metastatic renal cell carcinoma (mRCC) undergoing cytoreductive nephrectomy (CN).Methods: We retrospectively investigated the clinicopathological data of patients with mRCC from two Chinese hospitals (2008-2018). Patients were stratified and analyzed for survival prognosis using X-tile software, Kaplan-Meier curves, log-rank test, and univariate/multivariate Cox regression analyses.Results: The patients were divided into low NLR group (≤2.7) and high NLR group (>2.7) based on the optimal cutoff value of 2.7 obtained using the X-tile software, containing 137 and 93 patients, respectively. Kaplan - Meier analysis indicated that high NLR group had significantly inferior median progression-free survival (PFS) and overall survival (OS) than low NLR group (median PFS of 8.3 months vs. 17.9 months, p = 0.003 and median OS of 21.6 months vs. 45.1 months, p = 0.009). Multivariate Cox regression analysis showed that NLR was an independent prognostic factor for PFS (hazard ratio [HR], 1.4; 95% CI, 1.1-1.9; p = 0.022) and OS (HR, 1.5; 95% CI, 1.1-2.1; p = 0.015).Conclusions: Elevated preoperative NLR demonstrates significant association with poor survival in post-CN mRCC patients and may facilitate clinical decision-making.\",\"PeriodicalId\":9182,\"journal\":{\"name\":\"Biomarkers in medicine\",\"volume\":\" \",\"pages\":\"215-222\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2025-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11916357/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biomarkers in medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/17520363.2025.2471746\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/2/26 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17520363.2025.2471746","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/26 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

摘要

目的：本研究旨在确定术前中性粒细胞与淋巴细胞比值（NLR）在转移性肾癌（mRCC）行细胞减减性肾切除术（CN）患者中的预后价值。方法：回顾性分析中国两家医院2008-2018年mRCC患者的临床病理资料。采用X-tile软件、Kaplan-Meier曲线、log-rank检验和单因素/多因素Cox回归分析对患者进行分层和生存预后分析。结果：根据X-tile软件获得的最佳临界值2.7，将患者分为低NLR组（≤2.7）和高NLR组（>2.7），分别为137例和93例。Kaplan - Meier分析显示，高NLR组的中位无进展生存期（PFS）和总生存期（OS）明显低于低NLR组（中位PFS为8.3个月对17.9个月，p = 0.003，中位OS为21.6个月对45.1个月，p = 0.009）。多因素Cox回归分析显示，NLR是PFS的独立预后因素(危险比[HR]， 1.4；95% ci, 1.1-1.9；p = 0.022)和OS (HR, 1.5；95% ci, 1.1-2.1；p = 0.015)。结论：术前NLR升高与cn后mRCC患者的不良生存率显著相关，并可能促进临床决策。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

NLR as prognostic biomarker for metastatic renal cell carcinoma patients treated with cytoreductive nephrectomy.

Purpose: This study aimed to determine the prognostic value of preoperative Neutrophil-to-lymphocyte ratio (NLR) in patients with metastatic renal cell carcinoma (mRCC) undergoing cytoreductive nephrectomy (CN).

Methods: We retrospectively investigated the clinicopathological data of patients with mRCC from two Chinese hospitals (2008-2018). Patients were stratified and analyzed for survival prognosis using X-tile software, Kaplan-Meier curves, log-rank test, and univariate/multivariate Cox regression analyses.

Results: The patients were divided into low NLR group (≤2.7) and high NLR group (>2.7) based on the optimal cutoff value of 2.7 obtained using the X-tile software, containing 137 and 93 patients, respectively. Kaplan - Meier analysis indicated that high NLR group had significantly inferior median progression-free survival (PFS) and overall survival (OS) than low NLR group (median PFS of 8.3 months vs. 17.9 months, p = 0.003 and median OS of 21.6 months vs. 45.1 months, p = 0.009). Multivariate Cox regression analysis showed that NLR was an independent prognostic factor for PFS (hazard ratio [HR], 1.4; 95% CI, 1.1-1.9; p = 0.022) and OS (HR, 1.5; 95% CI, 1.1-2.1; p = 0.015).

Conclusions: Elevated preoperative NLR demonstrates significant association with poor survival in post-CN mRCC patients and may facilitate clinical decision-making.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Biomarkers in medicine 医学-医学：研究与实验

CiteScore

3.80

自引率

4.50%

发文量

审稿时长

6-12 weeks

期刊介绍： Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory. Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice. As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications. Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest. Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.